12. November 2020 | 10:03 CET
Alibaba, Silver Viper, Saturn Oil & Gas, CureVac: You need to know!
High fluctuation margins are currently being observed on the market. Due to the shift into cyclical stocks, especially tech stocks like Amazon, Alibaba or the Companies benefiting enormously from the Corona pandemic, like ZOOM or TeamViewer, are falling. Here, after a first commute, there are good buying opportunities. Gold and silver stocks should also be added to the watch list. The uncertainty is certainly not over.
time to read:
ISIN: CA8283341029 , CA80412L1076 , US01609W1027 , NL0015436031
Chances of share price explosion
The chart of the Canadian oil producer Saturn Oil & Gas is on the verge of breaking out, and this would be fundamentally justified. On the one hand, the Company is profiting from the resurgent oil price. On the other hand, the team around the experienced CEO John Jeffrey is continuously strengthened with top-class people who can master the aggressive acquisition strategy that has been issued. Jean-Pierre Colin, a manager who has advised not only high-ranking politicians but also completed several billion-dollar deals in his 40-year career, has now been brought on board as the top strategy consultant. Colin sold his Eleonor project to Goldcorp Inc. for more than CAD 1 billion, today known as Newmont Corporation.
When comes the boost?
For a long time, the share price of the Calgary-based Company floated in a range between CAD 0.08 and CAD 0.10. With the recent commitment from Colin, a clear turnover with rising prices comes into the share. According to market observers, major acquisitions should be pending soon. If these are announced, the short-sellers are likely to get cold feet. A vital mark at the moment is CAD 0.12.
Following the decision in the US elections and the announcement that a vaccine against the coronavirus may soon be available, the safe havens of gold and silver corrected sharply. However, the problems of enormous government debt and uncertainties are likely to persist. For investors, there is an opportunity to invest in cheap mining stocks. The Canadian exploration Company Silver Viper Minerals Corp. has also been hit hard. After peaking at around CAD 0.85, there has been a significant correction of no less than 50% since September.
Fundamentals on target
Silver Viper Minerals Corp. is a Canadian-based junior explorer focused on precious metals in Sonora, Mexico. The Company currently operates its La Virginia gold-silver project, formerly owned by Pan American Silver Corp. Drilling at La Virginia has identified a gold-silver vein up to 20 metres in diameter. Assessing the underground trend is part of this years drilling program. Positive outlier results from the drilling of 22.6 g/t gold and 1,431 g/t silver were the most significant.
Fresh money provides flexibility
In connection with a financing round from 2019, Silver Viper is now able to generate a further inflow of funds of around CAD 2.8 million. The financing included an early conversion right of the warrants as soon as the share price trades at an average of at least CAD 0.70 for ten consecutive days. This was achieved in September. CEO Steve Cope intends to use the new money to test other drill-ready anomalies, in addition to existing projects, that the Company has identified on the surface during the sampling program. The Chairman anticipates further momentum that could further increase the value of the Company this year.
In the shadow of BioNTech
Somewhat less noticed than the competitor from Mainz is the Tübingen Company CureVac. The share remains at EUR 51.40, roughly the same level as in mid-August. The Company, financed by Dietmar Hopp, is only marginally behind the conglomerate of BioNTech and Pfizer. The go-ahead for the decisive Phase III tests is to be given this year. CureVac plans to apply for a so-called rolling approval to the European Medicines Agency (EMA) in the first quarter of 2021. If all goes well, the vaccine could be available in mid-2021. Considering that there will be several vaccine suppliers, as the demand is enormous, there is still potential to catch up with the other players when evaluating CureVac.